Human medicines European public assessment report (EPAR): Beromun, tasonermin, Date of authorisation: 12/04/1999, Revision: 16, Status: Authorised
What is established Beromun is a medicinal product containing the active substance tasonermin, which is a recombinant form of human tumour necrosis factor alfa-1a (TNFα). The medicine is approved in the European Union for the treatment of soft-tissue sarcoma located in limbs (arms or legs), administered in combination with melphalan through a…
Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Date of authorisation: 25/08/2020, Revision: 11, Status: Authorised
What is established Idefirix (active substance: imlifidase) is a medicine authorised in the European Union to aid kidney transplantation in adults who are highly sensitised and therefore at high risk of rejecting a donor kidney. It works by enzymatically cleaving immunoglobulin G (IgG) antibodies in the blood, which are responsible for immune…
Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, Date of authorisation: 09/12/2021, Revision: 21, Status: Authorised
Evidence Dossier: Cibinqo (abrocitinib) for Atopic Dermatitis What is established Cibinqo, containing the active substance abrocitinib, is a medicine authorised in the European Union since December 2021 for the treatment of moderate to severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older. It is indicated for patients where…
Communicable disease threats report, 10 – 16 October, week 42
Health & Science Evidence Dossier: Communicable Disease Threats in Europe, 10 – 16 October 2026 This dossier summarizes information from the European Centre for Disease Prevention and Control’s (ECDC) weekly Communicable Disease Threats Report (CDTR) for week 42 of 2026, covering the period 10 to 16 October. The CDTR is aimed at…
Strengthening public health emergency operations centres in Europe through exchange of good practices
Strengthening Public Health Emergency Operations Centres in Europe Through Exchange of Good Practices What is established A three-day training workshop held in Ljubljana from October 5–7, 2026, focused on enhancing the capacities of Public Health Emergency Operations Centres (PHEOCs) in Europe. This event was jointly organised by the European Centre for Disease…
Human medicines European public assessment report (EPAR): Neuzafy, filgrastim, Status: Opinion
New Medicines and Opinions: Neuzafy (filgrastim) What is established Neuzafy is a biosimilar medicinal product containing filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF). Filgrastim works by stimulating the bone marrow to increase production and maturation of neutrophils, a type of white blood cell important in fighting infections. Its active mechanism targets the…
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion
Kizfizo (Temozolomide): New European Medicines Agency Opinion on Treatment for Glioma This dossier examines the recent positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding Kizfizo, a new formulation of the chemotherapy drug temozolomide. The medicine is intended primarily for treating glioblastoma multiforme and…
Human medicines European public assessment report (EPAR): Fovlussea, ranibizumab, Ophthalmologicals, Status: Opinion
What is established On 15 October 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the granting of marketing authorization for Fovlussea, a biosimilar drug to ranibizumab. Ranibizumab is a monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), a key…
Human medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 70, Status: Authorised
What is established Remicade (active substance infliximab) is a monoclonal antibody medicine authorised in the European Union since 1999. It is used primarily as an anti-inflammatory treatment in several autoimmune diseases where inflammation is pathological, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Infliximab works by targeting…
Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 14, Status: Authorised
Health & Science Evidence Dossier: Idelvion (albutrepenonacog alfa) for Haemophilia B What is established Idelvion is a medicinal product authorized for use in the European Union to prevent and treat bleeding episodes in patients with haemophilia B, an inherited disorder characterized by a deficiency of clotting Factor IX. The active ingredient, albutrepenonacog…